Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
Gemtuzumab
MeSH Descriptor Data 2025
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Gemtuzumab
Tree Number(s)
D09.408.051.247.500
D12.776.124.486.485.114.224.060.790
D12.776.124.790.651.114.224.060.790
D12.776.377.715.548.114.224.200.790
Unique ID
D000079982
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000079982
Scope Note
Immunotoxin that consists of an anti-CD33 (
CD33 ANTIGEN
) monoclonal antibody conjugated to
CALICHEAMICIN
. It is used for the treatment of
ACUTE MYELOID LEUKEMIA
.
Entry Term(s)
CMA 676
CMA-676
Gemtuzumab Ozogamicin
Gemtuzumab-Ozogamicin
Mylotarg
Pharm Action
Immunotoxins
Antineoplastic Agents, Immunological
Registry Numbers
93NS566KF7
0
8GZG754X6M
Related Numbers
8GZG754X6M
Public MeSH Note
2020; GEMTUZUMAB was indexed under AMINOGLYCOSIDES and ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2019; and under ANTIBODIES, MONOCLONAL 2000-2011
History Note
2020 (2000)
Date Established
2020/01/01
Date of Entry
2019/07/08
Revision Date
2019/04/29
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Carbohydrates [D09]
Glycosides [D09.408]
Aminoglycosides [D09.408.051]
Calicheamicins [D09.408.051.247]
Gemtuzumab [D09.408.051.247.500]
Inotuzumab Ozogamicin [D09.408.051.247.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ramucirumab [D12.776.124.486.485.114.224.060.866]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ramucirumab [D12.776.124.790.651.114.224.060.866]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ramucirumab [D12.776.377.715.548.114.224.200.866]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Expand All
Collapse All
Gemtuzumab
Preferred
Concept UI
M0398183
Registry Numbers
93NS566KF7
Related Numbers
8GZG754X6M
Scope Note
Immunotoxin that consists of an anti-CD33 (
CD33 ANTIGEN
) monoclonal antibody conjugated to
CALICHEAMICIN
. It is used for the treatment of
ACUTE MYELOID LEUKEMIA
.
Terms
Gemtuzumab
Preferred Term
Term UI
T000949339
Date
12/06/2018
LexicalTag
NON
ThesaurusID
CMA 676
Narrower
Concept UI
M0360010
Registry Numbers
0
Terms
CMA 676
Preferred Term
Term UI
T411114
Date
04/04/2000
LexicalTag
LAB
ThesaurusID
NLM (2000)
CMA-676
Term UI
T411115
Date
04/04/2000
LexicalTag
LAB
ThesaurusID
Mylotarg
Narrower
Concept UI
M0374887
Registry Numbers
0
Terms
Mylotarg
Preferred Term
Term UI
T431375
Date
12/19/2000
LexicalTag
TRD
ThesaurusID
US
Gemtuzumab Ozogamicin
Narrower
Concept UI
M0483090
Registry Numbers
8GZG754X6M
Terms
Gemtuzumab Ozogamicin
Preferred Term
Term UI
T000949340
Date
12/06/2018
LexicalTag
NON
ThesaurusID
Gemtuzumab-Ozogamicin
Term UI
T000949341
Date
12/06/2018
LexicalTag
NON
ThesaurusID
NLM (2009)
page delivered in 0.145s